Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of rifapentine丨cas 61379-65-5 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.
Specifications
|
Appearance: |
Brick-red to Dark red crystalline powder |
|
Assay: |
93.5% min (Calculated on the dried basis) |
|
Solubility: |
Soluble in chloroform/methanol, slightly soluble in ethanol/acetone/n-butyl alcohol, insoluble in water |
|
Identification: |
IR & HPLC positive |
|
pH: |
4.0–8.0 |
|
Any individual impurity: |
1.0% max |
|
Sum of impurities: |
3.0% max |
|
Heavy metals: |
20 ppm max |
|
Water: |
1.5%–5.0% |
|
Residue on ignition: |
0.2% max |
|
Ethanol: |
1.0%–3.5% |
|
Butyl alcohol: |
1.0% max |
Transport Information
|
Parameter |
Specification |
|
UN Number |
|
|
Class |
|
|
Packing Group |
|
|
H.S. Code |
2941903000999 |
|
Stability & Reactivity |
The product is chemically stable under standard ambient conditions. |
|
Storage |
Sealed in dry, Store in freezer, under -20°C |
|
Condition to Avoid |
|
|
Package |
Rifapentine丨CAS 61379-65-5 is a semisynthetic derivative of rifampin, belonging to the rifamycin class of antibiotics. It is primarily used for tuberculosis (TB) treatment, particularly for latent TB infection (LTBI) and active pulmonary TB.
Applications
1. Treatment of Tuberculosis (TB)
● Rifapentine is used in combination with other anti-tubercular agents such as isoniazid or moxifloxacin for the treatment of active TB.
● It is part of short-course regimens to enhance patient adherence due to less frequent dosing.
2. Latent TB Infection (LTBI)
● One of its most important applications is in the treatment of latent TB, preventing the progression to active disease.
● The 3HP regimen (once-weekly rifapentine + isoniazid for 12 weeks) is endorsed by the CDC and WHO due to its high completion rates and strong efficacy.
● The 1HP regimen (daily rifapentine + isoniazid for 1 month) is another promising short-course regimen under evaluation.
3. HIV-TB Co-infection Treatment
● Rifapentine-based regimens have shown effectiveness in HIV-positive patients, offering simpler and shorter treatment courses compared to traditional TB drugs.
4. Potential Use in Drug-Resistant TB
● Although not the first-line treatment for multidrug-resistant TB (MDR-TB), rifapentine is being explored in clinical studies for its utility in resistance-tailored regimens.
Benefits
1. Long Half-Life and Dosing Convenience
● Rifapentine丨CAS 61379-65-5 has a longer half-life than rifampin (~13–24 hours), enabling less frequent dosing (once or twice weekly), which improves patient adherence.
● This pharmacokinetic profile supports short-course and directly observed therapy (DOT) models.
2. High Potency Against Mycobacterium tuberculosis
● It has potent bactericidal activity against both replicating and semi-dormant TB bacilli.
● Active at lower doses and demonstrates concentration-dependent killing.
3. Improved Treatment Outcomes
● Short-course regimens with rifapentine have shown non-inferiority or superiority compared to traditional longer regimens in clinical trials.
● Lower pill burden and shorter duration contribute to higher treatment completion rates.
4. Strategic Public Health Tool
● As part of global TB eradication strategies, rifapentine is central to new treatment protocols aimed at reducing transmission, improving adherence, and lowering healthcare costs.
Conclusion
Rifapentine丨CAS 61379-65-5 is a vital antibiotic in tuberculosis control, offering shorter, more convenient regimens with improved compliance and treatment outcomes. Its role in both latent and active TB, especially in co-infection with HIV, marks it as a strategic tool in modern infectious disease management. As research continues to expand its use in resistance-prone TB and global health programs, rifapentine is poised to remain a cornerstone of TB therapy.

